Delcath Systems, Inc. (DCTH) Stock Faces Higher Risks Forward After Forming Double Bottom Pattern

September 8, 2018 - By Mary Kidd

Delcath Systems, Inc. (OTCMKTS:DCTH) Logo

The chart of Delcath Systems, Inc. (DCTH) shows a double bottom with $2.02 target or 4.00 % below today’s $2.10 share price. The 7 months chart pattern indicates high risk for the $1.96 million company. It was reported on Sep, 8 by Finviz.com. If the $2.02 price target is reached, the company will be worth $78,320 less. Double bottoms are rare but powerful chart patterns.

The stock increased 8.81% or $0.17 during the last trading session, reaching $2.1. About 26,808 shares traded or 175.52% up from the average. Delcath Systems, Inc. (OTCMKTS:DCTH) has 0.00% since September 8, 2017 and is . It has underperformed by 12.57% the S&P500.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company has market cap of $1.96 million. The firm is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It currently has negative earnings. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.